Richard Bernstein Advisors LLC Sells 65,636 Shares of Pfizer Inc. $PFE

Richard Bernstein Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 55.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,169 shares of the biopharmaceutical company’s stock after selling 65,636 shares during the quarter. Richard Bernstein Advisors LLC’s holdings in Pfizer were worth $1,329,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the business. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $32,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer in the second quarter worth about $33,000. Finally, True Wealth Design LLC boosted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.12 on Wednesday. The firm has a market cap of $154.22 billion, a PE ratio of 19.94 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The business’s fifty day simple moving average is $26.38 and its 200-day simple moving average is $25.49.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date was Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer’s eczema drug meets main goal in mid-stage trial
• Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
• Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
• Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer’s Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
• Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Morgan Stanley lowered their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Bank of America decreased their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. UBS Group started coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Finally, Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.